A Multicenter, Retrospective, Medical Record Review Of The Effectiveness Of Lanreotide Following Treatment With Octreotide In Patients With Neuroendocrine Tumors
Phase of Trial: Phase IV
Latest Information Update: 04 Sep 2017
At a glance
- Drugs Lanreotide (Primary) ; Octreotide
- Indications Neuroendocrine tumours
- Focus Therapeutic Use
- Sponsors Ipsen
- 28 Aug 2017 Planned End Date changed from 14 Jul 2017 to 14 Dec 2017.
- 28 Aug 2017 Planned primary completion date changed from 14 Jul 2017 to 14 Dec 2017.
- 18 Apr 2017 New trial record